Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer by Slevin, F et al.
Creative Commons licenses: This is an Open Access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial-ShareAlike 4.0 International (CC BY -NC -SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/).
Clinical Investigations
Original paper 
Ten-year longitudinal health-related quality of life 
following iodine-125 brachytherapy monotherapy 
for localized prostate cancer 
Finbar Slevin, FRCR1, Brinda Sethugavalar, FRCR1,a, Bashar Al-Qaisieh, PhD2, Peter Bownes, MSc2, Joshua Mason, PhD2,b, 
Jonathan Smith, FRCR3, David Bottomley, FRCR1, Ann M Henry, FRCR1 
1Department of Clinical Oncology, Leeds Teaching Hospital NHS Trust, Leeds, UK, 2Department of Medical Physics, Leeds Teaching Hospital 
NHS Trust, Leeds, UK, 3Department of Clinical Radiology, Leeds Teaching Hospital NHS Trust, Leeds, UK 
Current address: aJames Cook University Hospital, Middlesbrough, UK, bImperial College Healthcare NHS Trust, The Bays, St Mary’s Hospital, 
London, UK 
Abstract 
Purpose: This prospective longitudinal study quantifies health-related quality of life (HRQoL) up to 10 years fol-
lowing permanent iodine-125 (125I) prostate brachytherapy alone for localized prostate cancer. 
Material and methods: In total, 120 patients completed a validated expanded prostate cancer index composite 
(EPIC) questionnaire pre-treatment and at 8 time points after treatment (6 weeks, 6, 10, 18 months, and 2, 3, 5, 10 years). 
At each time point, clinically relevant small, moderate, and severe declines in HRQoL were defined as 0.2-0.5 SD, 
0.5-0.8 SD, and > 0.8 SD of baseline function for each of urinary, bowel, and sexual domains, respectively. 
Results: Response rates in the first two years were > 90%, but thereafter dropped to 75% and 48% at 5 and 10 years, 
respectively. 50 patients (41.6%) responded at all stages. Maximal deterioration in mean urinary and sexual summary 
scores was noted 6 weeks after implant, with severe urinary symptoms and moderate bowel/sexual symptoms. At 
6 months, urinary and bowel quality of life (QoL) had improved to mild impairment, which then fully resolved at 
10 months. Sexual QoL remained mildly impaired throughout the 10 years of follow-up. At 10 years, new mild impair-
ment of urinary and bowel QoL was found. 
Conclusions: Clinically mild changes in urinary, bowel, and sexual QoL are found 10 years after 125I monotherapy. 
The impairment in sexual function persists from treatment, but urinary and bowel symptoms are new at 10 years. 
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Purpose 
Prostate cancer is the commonest new cancer diag-
nosis in men in the Western World, with approximately 
48,500 new cases each year in the UK [1]. In those with 
early localized disease, the treatment options include ac-
tive surveillance, brachytherapy, radical prostatectomy, 
or external beam radiotherapy [2]. The majority of men 
are cured of their cancer, and may have to live many 
years with the sequelae of treatment. It is therefore es-
sential to have robust information about the long-term 
effects on urinary, bowel, hormonal, and sexual function. 
Few studies report long-term prospectively collected 
health-related quality of life (HRQoL) longitudinal data 
[3,4,5,6]. 
Material and methods 
Patient group 
The local research ethics committee approved this 
study and patients gave informed written consent. From 
March to September 2002, 150 consecutive patients with 
localized prostate cancer due to undergo iodine-125 (125I) 
prostate brachytherapy were invited to complete detailed 
HRQoL paper questionnaires documenting urinary, bow-
el, sexual, and hormonal function. 126 patients participat-
ed and were requested to complete questionnaires before 
brachytherapy, four to 6 weeks after the implant, every 
4 months in the first year, and then every 6 months in the 
second year as well as at the end of 3th, 5th, and 10th year. 
At the first two time points, patients completed the ques-
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tionnaires during their routine visits to the clinic. Subse-
quently, patients were mailed the questionnaire, which 
they completed at home and returned to the research 
coordinator. Those patients who did not respond within 
two weeks of mailing were reminded by telephone. The 
authors have previously reported clinicopathological 
data and 10-year outcomes for patients treated with 125I 
prostate brachytherapy in our center [7]. 
HRQoL instrument 
The expanded prostate cancer index composite (EPIC) 
was chosen because it is a well-validated comprehensive 
HRQoL instrument used in previous studies. It is one of 
the patient-reported outcome measures (PROMs) for as-
sessment of quality of life (QoL) included in the prostate 
cancer guidelines of the European Association of Urol-
ogy [2,3,8,9,10]. The detailed questionnaires record pa-
tient-derived information on urinary, bowel, sexual, and 
hormonal functions within separate sub-sections or do-
mains. Higher overall and domain scores (range, 0-100) 
represent better functioning and QoL, with the majority 
of questions using ordinal response scales (e.g., no, very 
small, small, moderate, big problem). It has advantages in 
that both a function and bother can be scored for each do-
main. Shorter 16- and 26-item versions of EPIC exist and 
are useful for clinical practice, but we wanted to obtain 
a greater detail of information, and therefore chose the 
original 50-item questionnaire. 
Treatment technique 
Patients who presented with a prostate volume > 50 ml 
underwent three months of neo-adjuvant hormonal treat-
ment, using either LHRH agonists or anti-androgens alone, 
before undergoing brachytherapy. Hormone therapy was 
discontinued one month after implantation. Some patients 
were also commenced on hormone treatment by the refer-
ring urologist before brachytherapy assessment and in this 
situation, hormone manipulation was also discontinued 
one month after brachytherapy. 
All patients were treated by implantation with 125I 
seeds as monotherapy. Planning objectives were a min-
imum peripheral dose of 145 Gy (prescription dose ac-
cording to TG43) to the prostate capsule plus a margin 
of 2 to 5 mm, a Vp100 (prostate volume covered by 100% 
of the prescription dose) of greater than 99%, and a D90 
(dose to 90% of the prostate) of approximately 180 Gy 
(124%). The D90 planned was expected to be higher than 
that achieved. Rectal dose constraints were mucosa V100 
< 0.9 cc, but no formal urethral dose constraints were 
used. Patients were treated with either a two-step or sin-
gle-step pre-planning technique using Seattle method, 
and prostate volume was estimated using TRUS to plan 
the treatment [11]. All implants were carried out using 
RAPID Strand™ (ONCURA, Arlington Heights, USA) 
stranded seeds. Post-implant dosimetry was performed 
by computed tomography (CT) at 6 to 8 weeks after im-
plantation, when the majority of edema should have set-
tled. Patients were not catheterized for post-implant CT 
dosimetry. 
Statistical analysis 
Overall and individual symptom-domain scores were 
recorded for each patient. Descriptive statistics (mean, 
standard deviation, and confidence intervals) were used 
to document HRQoL at each time point. Mean values at 
each time point were compared with the baseline values 
using 95% confidence intervals (95% CI), and statistical 
significance was compared using a paired t-test. No im-
putation of missing data was performed. A p value of 
< 0.05 was taken to indicate a statistically significant dif-
ference. However, to identify clinically relevant changes 
in HRQoL, small, moderate, and severe declines were de-
fined as 0.2-0.5 SD, 0.5-0.8 SD, and > 0.8 SD of baseline 
function for each of urinary, bowel, and sexual domains, 
respectively [12,13,14]. Regression analysis was applied 
to quantify any relationship between dosimetry parame-
ters and EPIC QoL scores. 
Results 
At pre-treatment, 126 out of the 150 invited partici-
pants completed the questionnaires. On review, 6 of 
these had undergone external beam radiotherapy with 
125I boost, and were therefore excluded from this analy-
sis. All of the remaining 120 patients presented with low- 
or intermediate-risk localized prostate cancer based on 
ESTRO/EAU/EORTC consensus guideline recommen-
dations, apart from one patient who had small volume 
Gleason 8, as per the International Society of Urologic 
Pathology (ISUP) grade 4 disease [15]. Mean age at the 
treatment was 63.9 (range, 43-76) years. Over half of all 
patients received neo-adjuvant hormone manipulation 
(62%, 74 patients); the majority for gland reduction but in 
some cases, it started prior to the referral for brachyther-
apy by the referring urologist. 
Table 1 presents all responses per domain over the 
10-year study period with HRQoL expressed in mean 
(SD). Table 2 shows the proportion of patients with small 
(0.2-0.5 SD), moderate (0.5-0.8 SD), and large (> 0.8 SD) 
declines in HRQoL for urinary, bowel, sexual, and hor-
monal domains at each time point up to 5 years. Ques-
tionnaire response rates in the first two years were > 90%, 
but thereafter dropped to 75% and 48% at 5 and 10 years, 
respectively. 50 patients (41.6%) responded at all stages. 
Response rates of the initial responders were at least 75% 
at each of the time points, with 77 patients responding at 
all time points. 
Urinary function 
As reported in our previously published work [16], 
a maximum deterioration was seen in urinary summa-
ry scores 6 weeks after implant. The drop in QoL was 
consistent across all four domains of function, bother, 
incontinence, and irritative or obstructive symptoms. At 
6 months, urinary QoL had improved but remained sta-
tistically significantly lower than baseline (Table 1 and 
Figure 1). By 10 months, the overall analysis showed uri-
nary summary scores had returned to pre-treatment lev-
els. Up to 18 months post-implant, reduced urinary QoL 
compared to baseline was seen, but at 2 years, symptoms 
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Table 1. The number of patients responding to expanded prostate cancer index composite (EPIC) health-rela-
ted quality of life (HRQoL) questionnaire for each time point over 10 years, with all responses per domain in 























No. of patients 120 110 116 115 113 111 96 90 57 
% of baseline 100 92 97 96 94 93 80 75 48 














































































































































































































































































































* SD of group mean 0.5-0.8, ** SD of group mean > 0.8 
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Table 2. The percentage of patients responding to expanded prostate cancer index composite (EPIC) health- 
related quality of life (HRQoL) questionnaire for each time point over 5 years, with small (0.2-0.5 SD), moder-



















No. of patients 120 110 116 115 113 111 96 90 
% of baseline 100 92 97 96 94 93 80 75 
Mean (SD) Percentage of patients per group at each time point (%) 
Urinary 
summary 
88.1 (11.8) < 0.2 SD 
0.2-0.5 SD 
0.5-0.8 SD 































92.6 (12.3) < 0.2 SD 
0.2-0.5 SD 
0.5-0.8 SD 































44.6 (29.4) < 0.2 SD 
0.2-0.5 SD 
0.5-0.8 SD 































83.9 (15.9) < 0.2 SD 
0.2-0.5 SD 
0.5-0.8 SD 





























10-year time point data not available 
returned to baseline and were maintained up to 5 years. 
At 10 years post-treatment, a mild reduction in urinary 
function (0.5-0.8 SD of group mean) was noted, with 
a small increase in urinary incontinence reported. 
Sexual function 
Baseline sexual QoL scores for our patients were low, 
with a mean summary score of 44.6 and a sexual function 
score of 37.7. The mean sexual summary and the sub-
scales of sexual function and bother never returned to the 
pre-treatment levels (Table 1 and Figure 2). Interestingly, 
the average bother score was higher at baseline at 60.7, 
and remained proportionally higher than the function 
score suggesting that the observed reduction in sexual 
function was accepted by this cohort of patients (Table 1). 
Increasing age was an independent prognostic factor at 































































Fig. 1. The change in mean expanded prostate cancer in-
dex composite (EPIC) urinary summary score in 10 years 
following 125I brachytherapy for all patients. P-value only 
shown if p < 0.05, with the comparison made to quality of 
life (QoL) at baseline
Fig. 2. The change in mean expanded prostate cancer in-
dex composite (EPIC) sexual summary score in 10 years 
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all time points for the mean summary and the sub-scale 
function, but not for the sub-scale bother (p < 0.01). 
Bowel function 
A small impact on bowel QoL was noted at 6 weeks, 
which returned to baseline within 6 to 10 months of im-
plantation for all patients. A small increase in bothering 
bowel symptoms (0.5-0.8 SD of group mean) was noted 
at 10 years, although bowel function remained stable 
(Table 1 and Figure 3). 
Post-implant dosimetry 
Computed tomography post-implant dosimetry was 
available in 110 out of 120 patients (91.7%). CT post-im-
plant dosimetry was undertaken at 6 weeks without cath-
eterization. The mean (SD) D90 was 146.1 (19) Gy. Using 
regression analysis, there was no correlation between 
mean central dose (a surrogate for urethral position in 
un-catheterized patients), prostate V150, or V200 as well 
as the EPIC urinary summary score (or any of the sub-
scores). Also, there was no relationship between the vol-
ume of rectum receiving 100% or 68% of the prescription 
dose (Vr100 or Vr68) and the EPIC bowel scores. 
Discussion 
This prospective longitudinal study demonstrates 
that after an initial period of mild to moderate symptoms, 
permanent prostate brachytherapy using 125I was well 
tolerated with a little deterioration in long-term QoL. 
The most robust information about long-term QoL 
following treatment for prostate cancer comes from ran-
domized trials where intervention groups have balanced 
baseline characteristics. A recent systematic review was 
published of randomized controlled trials and non-ran-
domized comparative studies of QoL after prostatecto-
my, brachytherapy, and external beam radiotherapy in 
patients with localized prostate cancer [17]. The authors 
concluded that brachytherapy patients mainly reported 
irritative/obstructive urinary problems up to around 
1 year, after which QoL gradually returned to baseline. 
Attempts to recruit patients into phase III trials 
comparing radical prostatectomy versus interstitial 
brachytherapy have been limited, as a significant pro-
portion of informed patients feel unable to commit to 
a random allocation of treatment. An early terminated 
SPIRIT trial [3] showed a comparison of QoL at a medi-
an of 5.2 years after treatment with either prostatectomy 
or brachytherapy (no neo-adjuvant hormone use). This 
cross-sectional study assessed 168 study eligible men, 
3.2 to 6.5 years after treatment, and demonstrated that 
those patients who underwent brachytherapy had better 
urinary, sexual, and patient satisfaction scores than men 
undergoing radical prostatectomy. The patients in the 
SPIRIT study had a mean 5-year EPIC sexual summary 
of 52.5, which is significantly higher than the mean 5-year 
EPIC sexual summary score of 36 for our patients. This 
may be because our group was an unselected cohort of 
consecutively treated patients. In addition, our patients 
were older, with mean age of 63.9 years compared to 
an average age of 61.4 years for patients treated with 
brachytherapy in the SPIRIT study. Furthermore, a num-
ber of our patients would likely not have been suitable for 
prostatectomy because of co-morbidity. 
Giberti et al. randomized 200 patients to either prosta-
tectomy or brachytherapy and assessed QoL at 6 months, 
1 year, and 5 years after treatment, although alternative 
QoL questionnaires to EPIC were used [18]. While pa-
tients treated with brachytherapy reported more irrita-
tive urinary symptoms at 6 months and 1 year, a better 
erectile function was also reported at these time points 
by brachytherapy patients. By 5 years, the authors found 
no difference between the groups in terms of urinary dis-
orders and sexual activity. However, this study did not 
assess QoL between 1 and 5 years. 
Hoffman et al. prospectively evaluated PROMs over 
5 years using the 26-item EPIC questionnaire in patients 
with favorable-risk prostate cancer managed with active 
surveillance, prostatectomy, external beam radiotherapy 
(EBRT), and brachytherapy (although patients treated 
with brachytherapy comprised only 6% of the cohort) 
[5]. For patients treated with brachytherapy, the authors 
observed worse urinary, sexual, and bowel function at 
1 year compared with active surveillance, but by 5 years, 
most functional differences across all active treatments 
had attenuated. However, patients treated with prosta-
tectomy reported worse urinary incontinence throughout 
5 years compared with all other treatment options. 
The prostate testing for cancer and treatment (Pro-
tecT) study compared outcomes after prostatectomy, 
EBRT, and active monitoring for 1,643 patients diagnosed 
with localized prostate cancer after prostate specific anti-
gen (PSA) testing [4]. Evaluation of PROMs demonstrat-
ed that prostatectomy had a greater initial and persisting 
effect on urinary continence than radiotherapy or active 
monitoring. Urinary incontinence after prostatectomy 

































Fig. 3. The change in mean expanded prostate cancer in-
dex composite (EPIC) bowel summary score in 10 years 
following 125I brachytherapy. P-value only shown if  
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2 years. Initial and persisting erectile dysfunction were 
also worse after prostatectomy than radiotherapy. 
Prospective longitudinal studies comparing non-ran-
domized cohorts of patients undergoing prostatectomy, 
brachytherapy, or external beam radiotherapy without 
hormone manipulation demonstrated that 3 years after 
treatment, brachytherapy patients experienced less uri-
nary incontinence, bowel effects, and sexual dysfunction, 
but more urinary irritative-obstructive symptoms [9,19]. 
This could indicate a tendency in overtime reduction of 
sexual function in brachytherapy patients that may be re-
lated to increasing age and/or a late effect of radiation [9]. 
Sanda et al. included men who underwent neo-adjuvant 
hormone treatment into a multi-center prospective longi-
tudinal study of all three treatment modalities [10]. The 
use of hormone manipulation in brachytherapy patients 
was associated with more sexual dysfunction and hor-
monal symptoms in the first 12 months after treatment, 
but by two years, sexual functioning had returned to 
a level similar to that of the cohort who had brachyther-
apy alone. 
A single-center prospective longitudinal study us-
ing RAND-36 generic health survey, EORTC core ques-
tionnaire QLQ-C30, and tumor-specific EORTC prostate 
cancer module (EORTC-PR25) in a cohort of 127 patients 
undergoing 125I brachytherapy demonstrated that after 
the first year, urinary and bowel symptoms returned to 
baseline and remained stable up to 6 years after treatment 
[20]. Similar to our cohort, sexual activity scores had di-
minished by 6 years in 70% of the patients treated in the 
absence of a significant reduction in sexual functioning. 
Indeed, emotional functioning scores had significantly 
improved at 6 years suggesting that although men may 
be less sexually active as time goes on, they may be less 
bothered about it. 
Evers et al. [21] prospectively evaluated the effect of 
neo-adjuvant hormones on urinary function (using the 
international prostate symptoms scores) and global QoL 
(EORTC-QLQ) in a cohort of 40 patients having 125I mono-
therapy with a follow-up period of 1 year. At baseline, 
the neo-adjuvant group reported worse urinary function, 
but experienced greater improvement in urinary func-
tion at 3 months when compared to those not receiving 
neo-adjuvant hormones. Other prospective longitudinal 
QoL studies suggested that short-term neoadjuvant hor-
mones did not appear to significantly affect long-term 
urinary or sexual function in brachytherapy patients [22]. 
At 10 years, we found small declines in urinary and 
bowel QoL. The relationship between the development of 
urinary and bowel symptoms at 10 years and brachyther-
apy was not clear in our study, but it could be as a con-
sequence of increasing patient age or a late effect of 
brachytherapy. The initial declines in urinary and bowel 
QoL had resolved to baseline by 2 years and 6-10 months, 
respectively, and urinary incontinence was noted at 
10 years rather than irritative/obstructive symptoms 
generally associated with brachytherapy. However, late 
urinary toxicity is recognized, and a study by Keyes et al. 
of 2,011 patients found prevalence of RTOG grade ≥ 2 to 
be 8.8% from 7 to 13 years post-brachytherapy. Greater 
baseline urinary symptoms, greater acute toxicity, larger 
prostate volume, higher D90, and age above 70 years were 
all associated with RTOG grade ≥ 2 late urinary toxicity 
[23]. Late radiation proctitis has also been reported, with 
rates of rectal bleeding of 5-7% and ulceration/fistula of 
0.6% [24]. 
It is well-known that with increasing age, sexual func-
tion decreases [25]. Free text responses from the QoL 
questionnaires in our study suggest some men were less 
bothered about their sexual function with increasing age 
(“I’m over 75”), or due to their own or partner’s co-mor-
bidity. This may be an explanation that in time, patients 
appear to be less bothered about their decreased sexual 
function. 
This study has limitations in that it was performed 
in a single-center, and baseline assessments of QoL were 
undertaken when neo-adjuvant had already been com-
menced in some patients. No interpretation of hormon-
al effects has therefore been undertaken. There was also 
some missing data. Although, data for the group mean 
HRQoL at the 10-year time point was known, the propor-
tions of patients with small, moderate, and large declines 
in HRQoL at the 10-year time point was unfortunately 
not available. Our cohort size was relatively small in com-
parison to other studies and by 10 years, the response rate 
to the questionnaires had reduced to 48% meaning that 
the results at that timepoint may not be representative 
of the whole cohort. Nevertheless, this does represent 
a reasonable response rate, with a long time after the 
treatment. For comparison, a study by Sanda et al. had 
a response rate of 59% at only 2 years [5]. Similar to other 
publications, post-implant dosimetry was not correlated 
with urinary or bowel toxicity [26,27]. 
Conclusions 
Permanent prostate brachytherapy using 125I has low 
toxicity up to 10 years after the treatment. When patients 
consider their treatment choice, they should be aware 
that their sexual function will temporarily deteriorate, 
and although improves, may not return to baseline levels 
in a long-term manner after the treatment. By 2 years, uri-
nary toxicity appears to return to baseline level. Mild uri-
nary and bowel symptoms are new at 10 years and may 
be either a late effect of brachytherapy or due to increas-
ing age. QoL measurements should remain an integral 
part of clinical trials in the setting of localized prostate 
cancer. 
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